Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride for Treatment-Resistant Schizophrenia
NCT05956600Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of amisulpride in schizophrenia and schizoaffective disorder, sponsored by University of California, Los Angeles. Primary endpoint: Positive and Negative Symptom Scale at 12 months. Planned start Nov 2023; status: withdrawn.
02
Drugs
amisulpride
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT05956600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956600.